Table 1. The correlation between ypN0 after NAT and clinicopathological characteristics.

Characteristics	All patients (n=184)	ypN0 (n=105)	%	P
Menopausal status				0.256
Menopause	67	35	52.2
No menopause	117	70	59.8
Pathological types				0.354
Ductal	156	87	55.8
Other	28	18	64.3
Ki-67				0.004
Low expression	34	13	38.2
High expression	150	92	61.3
Molecular subtypes				0.805
HER2+	89	53	59.6
HR+	52	28	53.8
HR-	37	25	67.6
TN	95	52	54.7
Clinical tumor staging				0.009
cT1	18	12	66.7
cT2	89	56	62.9
cT3	34	19	55.9
cT4	43	18	41.9
Clinical lymph node staging				<0.001
cN0	37	35	94.6
cN1	82	47	57.3
cN2	31	12	38.7
cN3	34	11	32.4
Radiologic response of the primary tumor on MRI				0.020
brCR	72	48	66.7
Non-brCR	48	23	47.9
Missing	64	34	53.1
Radiologic response of the lymph nodes				<0.001
ycN0	95	77	81.1
Non-ycN0	89	28	31.5
Pathologic response of the primary tumor				<0.001
bpCR (ypT0/is)	79	65	82.2
Non-bpCR	105	40	38.1

NAT, neoadjuvant therapy; ypN0, pathologically node-negative disease after NAT; HR, hormone receptor; brCR, breast radiologic complete response; ycN0, clinically node-negative disease after NAT; bpCR, breast pathologic complete response; N, number; HER2+, human epidermal growth factor receptor 2 positive; TN, triple-negative; MRI, magnetic resonance imaging.